Other · developed by Ultragenyx Pharm
Triheptanoin is a medium-chain triglyceride made of three odd-chain 7-carbon fatty acids (heptanoate). It provides calories and fatty acids that bypass long-chain fatty acid oxidation enzyme deficiencies for energy production, and is studied in long-chain fatty acid oxidation disorders, including carnitine palmitoyltransferase, VLCAD, LCHAD, trifunctional protein and CACT deficiencies, as well as Huntington disease.
Summary written with AI from the sources listed at the end of this page.
From the indications section of the FDA label (version of Jun 10, 2025). Read the full label for the exact wording, limitations and safety information.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT05933200 | Phase 3 | Long-chain Fatty Acid Oxidation Disorders (LC-FAOD) | Active not recruiting | RARE |
| NCT02453061 | Phase 2 | Huntington Disease | Completed | RARE |
| NCT02214160 | Phase 2 | Carnitine Palmitoyltransferase (CPT I or CPT II) Deficiency | Completed | RARE |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Long-chain Fatty Acid Oxidation Disorders (LC-FAOD)Carnitine Palmitoyltransferase (CPT I or CPT II) DeficiencyCarnitine-acylcarnitine Translocase (CACT) DeficiencyHuntington DiseaseTrifunctional Protein (TFP) DeficiencyVery Long Chain Acyl-CoA Dehydrogenase (VLCAD) Deficiency
Updated Oct 25, 2026. Something wrong or missing? Report it on the RARE page.
See RARE's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
RARE catalysts and pipeline →